BioSight
Therapeutics for Oncology and Hematological Disorders
Company Overview
Snapshot
Founded in November 1999 by Stela Gengrinovitch, PhD and Mark Gengrinovitch, BioSight operates with 1–10 employees. The company raised $62.5M across 5 funding rounds from 9 investors. In October 2023, BioSight was acquired by Ayala Pharmaceuticals, marking a significant exit for the biotechnology firm.
Business overview
BioSight is a clinical-stage biotechnology company focused on developing therapeutics for hematological malignancies and disorders. Its core product, BST-236 (INN aspacytarabine), is a proprietary anti-metabolite designed to deliver high-dose therapy with reduced systemic toxicity. The company primarily serves the oncology and hematology markets, operating within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals and Drugs Discovery & Development.
Strategic signal
In November 2022, BioSight initiated a Phase 1/2 clinical trial for aspacytarabine in combination with venetoclax for first-line AML induction therapy, followed by aspacytarabine consolidation. This development signals the company's continued commitment to advancing its lead product and expanding its potential applications in acute myeloid leukemia treatment, indicating a strategic focus on clinical validation and market expansion prior to its acquisition.
Log in to access full profile ›Company Intelligence Q&A
- What was BioSight's most recent corporate milestone?
- In October 2023, BioSight was acquired by Ayala Pharmaceuticals, leading to its inactive status.
- When did BioSight last raise a funding round?
- In December 2020, BioSight closed a Series C funding round with investments from Israel Biotech Fund and Arkin Bio.
- What is BST-236?
- BST-236 (INN aspacytarabine) is BioSight's proprietary anti-metabolite product, designed to enable high-dose therapy with reduced systemic toxicity, currently being investigated for acute myeloid leukemia (AML).
- Did BioSight receive any special designations for its lead product?
- In August 2020, BioSight was granted U.S. FDA Fast Track Designation for BST-236 for the treatment of Acute Myeloid Leukemia. Previously, in June 2019, the company received Orphan Drug Designation from the FDA for BST-236 for the same indication.
- What clinical trials has BioSight initiated recently?
- In November 2022, BioSight launched a Phase 1/2 clinical trial for aspacytarabine in combination with venetoclax for first-line AML induction therapy, followed by aspacytarabine consolidation.